- Conditions
- Nerve Block
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 1,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bone Mineralization, Adolescent Development
- Interventions
- Beverage containing calcium citrate malate, Beverage fortified with calcium citrate malate
- Dietary Supplement
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 11 Years to 15 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Healthy Participants
- Interventions
- BMS-986196, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more
- Conditions
- Diabetes Mellitus, Type 1, Pregnancy
- Interventions
- Bump2be, Routine Care
- Behavioral · Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Carcinoma, Midline
- Interventions
- GSK525762
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Polycythemia Vera, Essential Thrombocythemia
- Interventions
- RG7388, Pegasys
- Drug
- Lead sponsor
- John Mascarenhas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
- Interventions
- DR-01
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Irvine, California + 11 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 11
- States / cities
- Tampa, Florida • Baton Rouge, Louisiana • Baltimore, Maryland + 5 more
- Conditions
- Healthy Volunteer
- Interventions
- BION-1301
- Drug
- Lead sponsor
- Chinook Therapeutics, Inc.
- Industry
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Gradual Exposure (EXP-G), Variable Exposure (EXP-V)
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- HER2-positive Breast Cancer, Metastatic Breast Cancer
- Interventions
- Pertuzumab, Trastuzumab, eribulin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- ME-401, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Deepa Jagadeesh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced HER2+Breast Cancer
- Interventions
- Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Los Angeles, California
- Conditions
- Advanced Solid Tumours
- Interventions
- AZD1775, MEDI4736
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
- Conditions
- Solid Tumor, Adult
- Interventions
- HMPL-A830
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Orange, California • Coral Springs, Florida • Plantation, Florida + 3 more
- Conditions
- Hypotension
- Interventions
- Phenylephrine
- Drug
- Lead sponsor
- West-Ward Pharmaceutical
- Industry
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 10
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia • Miami, Florida + 7 more
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Hypertension
- Interventions
- Carvedilol CR capsules, Placebo, Lisinopril
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 20
- States / cities
- Anniston, Alabama • Glendale, Arizona • Anaheim, California + 17 more
- Conditions
- Cytomegalovirus
- Interventions
- mRNA-1647, Placebo
- Biological · Other
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 9 Years to 25 Years
- Enrollment
- 873 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 44
- States / cities
- La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more
- Conditions
- Opioid Use Disorder, Behavioral Symptoms, Psychiatric or Mood Diseases or Conditions
- Interventions
- Remote Motivational Enhancement (RME) Intervention Arm, Information Only
- Behavioral · Other
- Lead sponsor
- Cambridge Health Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1), Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
- Device
- Lead sponsor
- Boris Kovatchev, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Cardiovascular Disease
- Interventions
- AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
- Interventions
- Venetoclax, Selinexor, Cytarabine, Fludarabine, Filgrastim, Methotrexate, methotrexate/hydrocortisone/cytarabine
- Drug · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 8
- States / cities
- San Diego, California • Boston, Massachusetts • New York, New York + 5 more